[Effect of buflomedil on the behavior of platelet aggregation and its clinical evaluation in elderly patients with chronic cerebrovascular insufficiency].

Abstract

An examination was made of the behaviour of platelet function after a single i.v. injection of 150 mg Buflomedil in 8 non-diabetic vasculopathic patients. The drug was followed by a significant reduction of the platelet aggregability induced by ADP and adrenaline, but not by collagen, and did not alter the percentage of reversible circulating platelet aggregates. Its action was limited in time, since no activity was observed after 24 hr. The drug was also clinically evaluated in 30 patients aged over 80 yr with chronic cerebrovascular insufficiency, following treatment with 100 mg/day i.v. for 20 days, and then 450 mg/day per os for 80 days. Significant improvements were noted in vertigo, tinnitus, lapses of memory, and the ability to remember numbers. The results were less impressive with regard to insomnia, migraine, and asthenia.

• Authors: A Cajozzo, V Abbadessa, M Musso, E Iannitto
• Journal: Minerva medica (Minerva Med) Vol. 74 Issue 28-29 Pg. 1727-31 (Jul 14 1983) ISSN: 0026-4806 [Print] Italy
• Vernacular Title: Effetti del buflomedil sul comportamento dell'aggregabilità piastrinica e sua valutazione clinica in pazienti anziani affetti da insufficienza cerebrovascolare cronica.
• PMID: 6346139 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Pyrrolidines
• buflomedil

Topics

• Aged
• Chronic Disease
• Clinical Trials as Topic
• Female
• Humans
• Intracranial Arteriosclerosis (drug therapy)
• Male
• Memory Disorders (drug therapy)
• Middle Aged
• Migraine Disorders (drug therapy)
• Platelet Aggregation (drug effects)
• Pyrrolidines (therapeutic use)
• Sleep Initiation and Maintenance Disorders (drug therapy)
• Tinnitus (drug therapy)
• Vertigo (drug therapy)